| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7858594 | NOVARTIS | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
Sep, 2023
(7 months ago) | |
| US7589079 | NOVARTIS | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
Sep, 2023
(7 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6395716 | NOVARTIS | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
Aug, 2019
(4 years ago) | |
| US7795238 | NOVARTIS | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
Aug, 2019
(4 years ago) | |
| US6566344 | NOVARTIS | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
Aug, 2019
(4 years ago) | |
| US6444652 | NOVARTIS | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
Aug, 2019
(4 years ago) | |
| US6569837 | NOVARTIS | β-L-2′-deoxy pyrimidine nucleosides for the treatment of hepatitis B |
Oct, 2020
(3 years ago) | |
Tyzeka is owned by Novartis.
Tyzeka contains Telbivudine.
Tyzeka has a total of 7 drug patents out of which 7 drug patents have expired.
Expired drug patents of Tyzeka are:
- US6395716
- US7795238
- US6566344
- US6444652
- US6569837
- US7858594
- US7589079
Tyzeka was authorised for market use on 28 April, 2009.
Tyzeka is available in tablet;oral, solution;oral dosage forms.
Tyzeka can be used as treatment of chronic hepatitis b in adult patients, treatment of chronic hepatitis b in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (alt or ast) or histologically active disease.
Drug patent challenges can be filed against Tyzeka from 25 October, 2010.
The generics of Tyzeka are possible to be released after 11 September, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 25, 2011 |
| M(M-124) | Jan 28, 2016 |
Drugs and Companies using TELBIVUDINE ingredient
NCE-1 date: 25 October, 2010
Market Authorisation Date: 28 April, 2009
Treatment: Treatment of chronic hepatitis b in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (alt or ast) or histologically active dise...
Dosage: SOLUTION;ORAL; TABLET;ORAL
TYZEKA family patents
